Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib

The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Kenichiro, Kawakado, Keita, Kawajiri, Tomoka, Nishi, Tatsuya, Makimoto, Go, Tamura, Tomoki, Kuyama, Shoichi, Tanimoto, Mitsune
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434540/
https://www.ncbi.nlm.nih.gov/pubmed/32296006
http://dx.doi.org/10.2169/internalmedicine.4449-20
Descripción
Sumario:The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutation-positive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.

Ejemplares similares